Kyverna Therapeutics, Inc. (KYTX) Financial Ratios
4 years of historical data (2021–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
1.34
↑+149% vs avg
5yr avg: 0.54
30Y Low0.5·High0.5
ROE
↑
-80.7%
↓+98% vs avg
5yr avg: -4622.6%
30Y Low-126%·High-81%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KYTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Kyverna Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $407M | $143M | — | — | — |
| Enterprise Value | $319M | $55M | — | — | — |
| P/E Ratio → | -2.79 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 1.34 | 0.54 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KYTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
KYTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -80.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Operating Margin | — | — | — | -418.3% | -465.8% |
| Net Profit Margin | — | — | — | -411.3% | -465.9% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | -80.7% | -80.7% | -126.0% | -13661.0% | — |
| ROA | -67.1% | -67.1% | -85.0% | -37.9% | -30.8% |
| ROIC | -106.0% | -106.0% | -217.1% | — | — |
| ROCE | -87.4% | -87.4% | -113.2% | -47.2% | -37.9% |
KYTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $97M exceeds total debt of $8M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.18 | 0.23 | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.33 | -0.52 | -0.58 | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -1004.25 | -1004.25 | -333.72 | -452.06 | -8782.00 |
Net cash position: cash ($97M) exceeds total debt ($8M)
KYTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Kyverna Therapeutics, Inc.'s current ratio of 8.61x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.45x to 8.61x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 8.61 | 8.61 | 3.05 | 4.45 | 4.84 |
| Quick Ratio | 8.61 | 8.61 | 3.05 | 4.45 | 4.84 |
| Cash Ratio | 8.47 | 8.47 | 2.90 | 4.29 | 4.78 |
| Asset Turnover | — | — | — | 0.10 | 0.07 |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
KYTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Kyverna Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $38M | $674M | $26M | $26M |
Peer Comparison
Compare KYTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KYTXYou | $407M | -2.8 | — | — | — | — | -80.7% | -106.0% | — |
 CABA | $409M | -2.4 | — | — | — | — | -127.0% | -429.6% | — |
 AUTL | $410M | -1.8 | — | — | -1293.5% | -2385.6% | -81.9% | -204.1% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 LEGN | $5B | -8.9 | — | — | 60.3% | -13.3% | -29.1% | -12.7% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 ALLO | $521M | -2.6 | — | — | — | — | -53.4% | -41.7% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
See KYTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KYTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KYTX vs CABA
Side-by-side business, growth, and profitability comparison vs Cabaletta Bio, Inc..
Start ComparisonKYTX — Frequently Asked Questions
Quick answers to the most common questions about buying KYTX stock.
What is Kyverna Therapeutics, Inc.'s P/E ratio?
Kyverna Therapeutics, Inc.'s current P/E ratio is -2.8x. This places it at the 50th percentile of its historical range.
What is Kyverna Therapeutics, Inc.'s ROE?
Kyverna Therapeutics, Inc.'s return on equity (ROE) is -80.7%. The historical average is -103.3%.
Is KYTX stock overvalued?
Based on historical data, Kyverna Therapeutics, Inc. is trading at a P/E of -2.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.